Imagine you have a promising molecule, assurance from clinicians but no factory to produce it. Or even worse, your current plant is maxed out, your capital exhausted, and regulatory demands keep intensifying. That’s the point where many pharma companies look toward third-party pharma manufacturing. It’s not just outsourcing — it’s a shortcut through infrastructure challenges, a way to scale faster, and a bridge over regulatory hurdles.